Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase whose activity is critical for cancer cell proliferation, survival, migration, and invasion.1 FAK overexpression has been documented in several solid tumours, including mesothelioma, and haematological malignancies,1–5 but FAK is detected at low levels in normal tissues or benign tumours.2 FAK overexpression may relate to prognosis in various human malignancies3,5 and is therefore an attractive target for anticancer therapy. This evidence concerns the gene PTK2 and benign neoplasm.